Does Wegovy Cause Dizziness? FDA Label, Mechanisms & Management Evidence Review

At a glance

• Wegovy §6.1 lists dizziness at 8% on semaglutide 2.4 mg vs 4% on placebo in the pooled adult obesity program; drug-attributable share roughly 4 percentage points^[4].
• The §6.1 dizziness column includes postural dizziness per the table footnote — orthostatic light-headedness on standing is captured in the same line.
• Three mechanisms drive the signal: dehydration from GI losses (§5.5), orthostatic hypotension from rapid weight loss (~14.9% body-weight loss by week 68 in STEP-1^[1]), and hypoglycemia in T2D combination therapy (§5.4)^[4].
• Hypoglycemia is rare in the obesity population without diabetes. The SELECT trial (n=17,604, mean 39.8 months) reported no signal of severe hypoglycemia in non-diabetic patients on semaglutide 2.4 mg^[3].
• T2D patients on Wegovy plus insulin or a sulfonylurea need a prescriber-led dose-down per §5.4: “consider reducing the dose of concomitantly administered insulin or insulin secretagogue.”
• Pediatric rate is similar: dizziness 8% on Wegovy vs 3% on placebo in adolescents aged 12+ (N=133 vs 67)^[4].
• Glucose check first in T2D combination therapy. Dizziness with shakiness, sweating, or confusion is a fingerstick, not a glass of water.

What the Wegovy FDA label says about dizziness

Unlike the Mounjaro label (where dizziness is not a separately tabulated §6.1 line), the Wegovy DailyMed label lists dizziness directly in the §6.1 adverse-reactions table^[4]. The pooled adult Wegovy 2.4 mg injection data (N=2,116) versus placebo (N=1,261) report dizziness at 8% on drug versus 4% on placebo. A table footnote reads “Includes dizziness and dizziness postural,” meaning the line captures both non-postural light-headedness and orthostatic (positional) dizziness in a single column. Dizziness also appears in the patient-counseling section as a hypoglycemia symptom and (as “fainting or feeling dizzy”) as a sign of serious allergic reaction.

The patient-counseling section then deepens the picture by explicitly placing dizziness inside the hypoglycemia symptom list: “Signs and symptoms of low blood sugar may include: dizziness or light-headedness, sweating, shakiness, blurred vision, slurred speech, weakness, anxiety, hunger, headache, irritability or mood changes, confusion or drowsiness, fast heartbeat, feeling jittery.”^[4] And it lists “fainting or feeling dizzy” as a red-flag symptom of a serious allergic reaction warranting immediate discontinuation. The label therefore treats dizziness both as a stand-alone §6.1 adverse reaction and as a diagnostic prompt for two other clinical pictures.

Mechanism #1 — dehydration from GI losses plus blunted thirst

The obesity-population dominant mechanism. Wegovy §5.5 specifically warns about acute kidney injury from volume depletion driven by GI adverse reactions^[4]:

The chain is straightforward: STEP-1 reported nausea at 44%, vomiting at 24%, diarrhea at 30% on Wegovy 2.4 mg^[1], and the slowed gastric emptying plus GLP-1-mediated appetite and thirst suppression reduces voluntary fluid intake. The result is hypovolemia, which surfaces clinically as orthostatic light-headedness — fine sitting or lying, light-headed within seconds of standing. Patients on a concomitant SGLT2 inhibitor (Jardiance, Farxiga, Invokana, Steglatro) compound the risk because the SGLT2 mechanism is obligate osmotic diuresis at all times, not just during GI flares.

Practical management is fluid tracking (2.5–3 L per day target) plus oral rehydration solution (LMNT, Liquid IV, DripDrop, Pedialyte) during active GI symptoms rather than plain water — the added sodium and potassium prevent the hyponatremia that heavy GI losses plus water-only rehydration can produce. For the full GI-management protocol see our Wegovy nausea evidence review.

Mechanism #2 — orthostatic hypotension from rapid weight loss

This is the mechanism most likely to surface in months 3–6 of Wegovy therapy, when meaningful weight loss has already accumulated. STEP-1 documented a mean body-weight reduction of 14.9% at week 68 on Wegovy 2.4 mg versus 2.4% on placebo^[1]. Antihypertensive doses calibrated to a patient’s starting weight can become overshooting once 10–20% of body weight has been lost, with the same patient experiencing systolic blood pressure 15–25 mmHg lower than pre-treatment baseline. Light-headedness on standing — especially after sitting for prolonged periods — is the cardinal symptom. Patients on diuretics (HCTZ, chlorthalidone, indapamide, loop diuretics), alpha-blockers, beta-blockers, or multi-agent antihypertensive regimens are at highest risk.

SELECT (Lincoff 2023 NEJM, n=17,604, mean follow-up 39.8 months) is the largest long-term safety dataset for semaglutide 2.4 mg in the obesity population. The trial reported a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease^[3], with no signal that the documented small mean heart-rate rise or the labeled dizziness rate translated into cardiovascular harm at the population level. The practical implication is that antihypertensive de-prescribing is part of the long-term Wegovy treatment success picture — not a failure signal — and home blood-pressure tracking every 2–3 months once meaningful weight loss has begun catches the over-medicated patient before the orthostatic symptoms reach syncope.

Mechanism #3 — hypoglycemia (rare in obesity-only, real in T2D combination therapy)

Wegovy §5.4 addresses hypoglycemia explicitly^[4]:

In the obesity-without-diabetes population, hypoglycemia is rare: SELECT (n=17,604 patients with obesity and cardiovascular disease but without diabetes) reported no meaningful severe-hypoglycemia signal on semaglutide 2.4 mg over a mean 39.8 months of follow-up^[3]. The picture changes in patients with T2D, particularly in combination therapy. STEP-2 (Davies 2021 Lancet, n=1,210 with T2D and overweight/obesity on background metformin ± sulfonylurea or SGLT2) reported documented symptomatic hypoglycemia in 6% on semaglutide 2.4 mg versus 3% on placebo, with most events occurring in patients on background sulfonylurea^[2]. The Wegovy §6.1 adult pooled table also lists “hypoglycemia in T2DM” at 6% on Wegovy vs 2% on placebo — a T2D-stratified adverse reaction, not a general adverse reaction.

Why this matters for dizziness: every hypoglycemia symptom in the patient labeling — dizziness, light-headedness, sweating, shakiness, blurred vision, slurred speech, weakness — can present as the chief complaint of a mild-to- moderate hypoglycemic event, sometimes before the patient registers a feeling of being “low.” In T2D patients on Wegovy plus insulin, a sulfonylurea (glipizide, glyburide, glimepiride), or a meglitinide (repaglinide, nateglinide), starting Wegovy without a dose-down of the insulin or insulin secretagogue is the single most common pathway to symptomatic hypoglycemia. The standard interpretation of §5.4 is to reduce the sulfonylurea dose by 25–50% (e.g., glipizide 10 mg twice daily → 5 mg twice daily) or to reduce basal insulin by 10–20% when initiating Wegovy.

When dizziness on Wegovy is not just titration

A subset of dizziness presentations on Wegovy are warning signs of something serious. The clinical patterns below should prompt prescriber contact or emergency evaluation regardless of where you are in titration.

Practical management protocol

The protocol stacks — doing all of the relevant interventions together produces more reliable resolution than any single change.

Hydration and electrolyte tracking

Target 2.5–3 L of non-caffeinated fluid per day, sipped rather than chugged (large bolus volumes can trigger nausea on semaglutide). During active GI flares, supplement with an oral rehydration solution (LMNT, Liquid IV, DripDrop, Pedialyte) rather than plain water — the sodium and potassium content prevents the hyponatremia that water-only rehydration can cause when GI losses are heavy. Patients on SGLT2 inhibitors (Jardiance, Farxiga, Invokana, Steglatro) should treat the combined fluid target as a floor rather than a goal.

Orthostatic technique

Stand up slowly from sitting or lying positions. Sit on the edge of the bed for 30–60 seconds before standing. Avoid prolonged stationary standing (e.g., showers, long lines) early in the day. Compression stockings can help patients with documented orthostatic hypotension. Keep blood pressure monitoring at home and report sustained drops to the prescriber — antihypertensive dose reductions are part of the long-term Wegovy response, not a failure signal. Reductions in calcium-channel blocker, ACE-inhibitor, or ARB dose are common 4–6 months into therapy once meaningful weight loss has accumulated.

Combination-therapy glucose discipline (T2D only)

T2D patients on Wegovy plus insulin or a sulfonylurea should expect, and ideally request, an explicit dose-down plan at Wegovy initiation. A reasonable starting point per §5.4^[4] is a 25–50% sulfonylurea reduction (glipizide 10 mg twice daily → 5 mg twice daily) or a 10–20% basal-insulin reduction. Continuous glucose monitoring (CGM) is the single highest-yield tool: it converts “possibly low” dizziness into a definitive diagnostic call within seconds. If a CGM is not in place, carry a fingerstick meter and glucose tablets at all times during the first 8 weeks of combination therapy.

Dose stability during active symptoms

The Wegovy titration ladder (0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg over 16 weeks) is flexible. The standard clinical response to dizziness episodes at a given dose step is to stay at the current dose for an additional 4 weeks rather than escalate on schedule. Pushing through escalation with unresolved symptoms is the path to drug discontinuation; an extra month at the lower dose is almost always the better move.

Medication review

Ask the prescriber to review the full home medication list for dizziness-prone agents: antihypertensives (especially after weight loss), benzodiazepines, opioids, gabapentin, pregabalin, tricyclic antidepressants, antihistamines (meclizine, dimenhydrinate, diphenhydramine), and centrally acting muscle relaxants. T2D patients on insulin or a sulfonylurea should use the same review to discuss formal dose adjustment of the diabetes regimen.

How Wegovy dizziness compares to Ozempic, Mounjaro, and Zepbound

Ozempic (semaglutide 0.5–2.0 mg): same molecule as Wegovy at lower doses, indicated for T2D rather than chronic weight management. The Ozempic label does not separately tabulate dizziness in §6.1, in part because the SUSTAIN T2D pivotal pool runs at 0.5 mg and 1.0 mg rather than the 2.4 mg Wegovy dose; the §5 warnings architecture is identical, and the patient-labeling hypoglycemia symptom list is the same.

Mounjaro (tirzepatide 2.5–15 mg, T2D): dizziness is not separately tabulated in the SURPASS-1 §6.1 most-common AE table. On the Mounjaro label it appears as a hypoglycemia symptom and as a serious-allergic-reaction symptom. For the full Mounjaro picture, see our Mounjaro dizziness evidence review.

Zepbound (tirzepatide 2.5–15 mg, obesity): same molecule as Mounjaro at the same dose strengths but in the SURMOUNT-1 obesity population (non-diabetic). The dizziness picture in non-diabetic Zepbound patients tracks dehydration and rapid-weight-loss orthostatic shifts (similar to non-diabetic Wegovy), not hypoglycemia, because SURMOUNT-1 reported near-zero hypoglycemia rates in the non-diabetic obesity population.

The cross-class takeaway: in any GLP-1 used for obesity, dizziness is dominated by dehydration and rapid-weight-loss orthostatic shifts, with hypoglycemia almost never the load-bearing cause unless the patient also has T2D and is on insulin or a sulfonylurea.

When to call your doctor

Call the prescribing clinician within 24–72 hours for any of the following, even if symptoms have already resolved:

• Recurrent orthostatic light-headedness on standing — may need antihypertensive dose review.
• Dizziness episodes that pattern with GI adverse reactions (worse after vomiting or diarrhea, better after fluids) and have not resolved within 48 hours of starting an oral rehydration protocol.
• Any episode of symptomatic hypoglycemia (dizziness with shakiness/sweating/confusion confirmed by fingerstick or CGM <70 mg/dL) in a combination-therapy T2D patient — the insulin or sulfonylurea dose likely needs adjustment per §5.4^[4].
• Dizziness persisting more than 2 weeks at a stable dose with no clear precipitant.

Seek emergency care (911 or ED) for any of the red-flag symptoms listed in the “not just titration” section above — allergic-reaction signs, chest pain, thunderclap headache, focal neurologic deficits, syncope, or intractable vomiting.

Related research and tools

• Mounjaro dizziness: FDA label, mechanisms & management — the T2D-population sister article, with the hypoglycemia-first differential and the Mounjaro §5.3 warning architecture.
• Wegovy heart palpitations: FDA label, STEP-1 & SELECT — cardiovascular signal sibling. Heart-rate rise plus dizziness with chest pain is the urgent-evaluation combination.
• Wegovy fatigue: STEP-1 rates, mechanism & management — sibling symptom-series article covering the overlapping caloric-deficit and dehydration mechanisms.
• Wegovy acid reflux and GERD: FDA label rates and mechanism — sibling article on the upstream GI-symptom layer that drives dehydration.
• GLP-1 side effect questions answered — the Q&A hub covering every common patient question across the class.
• GLP-1 side effect timeline tool — interactive view of when each side effect peaks and resolves, by drug and week.

Important disclaimer. This article is educational and does not constitute medical advice. Dizziness management decisions on Wegovy should always be made with your prescribing clinician, particularly if you are on insulin, a sulfonylurea, an SGLT2 inhibitor, multi-agent antihypertensive therapy, or if you have diabetic gastroparesis, autonomic neuropathy, chronic kidney disease, heart failure, or a history of arrhythmia or syncope. If you have any of the red-flag symptoms listed above (anaphylaxis signs, chest pain, sudden severe headache, focal neurologic deficits, syncope, or intractable vomiting), seek care promptly.